Nociceptin (1-13) amide

Nociceptin (1-13) amide (CPC catalog code OPIO-011) is a synthetic opioid-receptor research peptide in the opioid category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Nociceptin (1-13) amide as a reference standard in opioid workflows — for example, opioid-receptor binding and selectivity profiling and β-arrestin recruitment and biased-agonism studies. Human clinical evidence is not established.

No. Nociceptin (1-13) amide is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a opioid workflow, Nociceptin (1-13) amide is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. GTPγS binding, cAMP HTRF, and β-arrestin PathHunter assays.

Store lyophilized at −20 °C. Handle as Schedule research reagents where applicable. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for OPIO-011. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.